by EqualOcean (EO) Podcasts
Founded in October 2018, EqualOcean International is an international information service provider and investment research firm that aims to become a global platform for industrial innovation. EqualOcean took upon itself the mission of assisting promising Chinese companies in their quest to break into the global market. Join host Jason Poon for impactful news covering the technology, health, automotive, and consumer sectors.
Language
🇺🇲
Publishing Since
11/23/2022
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
December 7, 2022
<p>Hello from EqualOcean. I am your host Jason Poon, and the sector I will be covering today is the financial sector. </p> <p>Sunshine Insurance Group (Chinese: 阳光保险集团) has recently passed the listing decision of the Hong Kong Stock Exchange. According to the post-decision information, the joint sponsors of the company are Huatai Securities (Chinese: 华泰国际)、CICC (Chinese: 中金公司)、UBS (Chinese: 瑞银集团) and CCBI (Chinese: 建银国际).</p> <p>The funds raised will be used to strengthen the company's capital base to support the continued growth of the business.</p> <p>Sunshine Insurance is a Chinese private insurance services group, operating life and health insurance through Sunshine Life, property and casualty insurance through Sunshine Property and Casualty, and managing funds through Sunshine Capital Management. Sunshine Insurance may become the tenth listed insurance company in China.</p> <p>In terms of operating results, Sunshine Insurance's total premium income showed an overall growth trend, but net profit declined in the first half and first three quarters of 2022. From 2019 to 2021, the company achieved a total premium income of CNY 87.91 billion, CNY 92.57 billion and CNY 101.76 billion, respectively. The total premium income in the first half of 2022 was CNY 62.95 billion, an increase of 14.31% compared with the same period of the previous year.</p> <p>The Five famous insurance companies in China include China Life Insurance Company Limited (Chinese: 中国人寿, China Life, 601628:SH), Ping An Insurance (Group) Company of China, Ltd. (Chinese: 中国平安, PingAn, 601318: SH), The People's Insurance Company (Group) of China Limited (Chinese: 中国人保, PICC, 601319:SH), China Pacific Insurance (Group) Co., Ltd. (Chinese: 中国太保, CPIC, 601601:SH), and New China Life Insurance Company Ltd.(Chinese:新华保险, NCI, 601336:SH).</p> <p><br></p> <p>Please follow us on our Chinese and English websites, cn.equalocean.com and equalocean.com, to learn more about our business</p> <p><br></p>
December 2, 2022
<p>Hello from EqualOcean, I am your host Jason Poon, and the sector I will be covering today is the consumer sector. </p> <p>The Chinese B2B intelligent marketing company Bailian.AI (Chinese: 百炼智能) raised CNY 100 million (USD 13.8 million) from Pre-B series funding round on 7 November, 2022. The financing was led by Enlight Growth Partners (Chinese: 明裕创投) and Fore Bright Capital (Chinese: 光远投资), followed by DeTong Capital (Chinese: 德同资本), and continued to be increased by the previous shareholders Orient Capital (Chinese: 东方嘉富) and Yunqi Partners (Chinese: 云启资本).</p> <p>The funds will be used to strengthen the marketing, develop products, improve the B2B marketing product matrix and the competitive barrier of AI technology.</p> <p>Bailian.AI is a Chinese B2B intelligent marketing service provider, founded in 2018, providing data-driven intelligent marketing SaaS products as well as digital solutions for companies with B2B marketing needs. It is focused on helping companies improve their marketing efficiency from market insights to sales lead development, screening, contacting and conversion through AI technology.</p> <p>Feng Shicong, the founder and CEO of Bailian.AI, said that the company's objective is to become a unicorn in the B2B intelligent marketing industry and to become ZoomInfo in China.</p> <p>In terms of business model, Bailian.AI chooses to serve medium and large enterprises with more purchasing power and innovation. At the industry level, the company has now covered a wide range of fields such as technology, energy, fast-moving consumer goods, finance and production, and has now achieved significant growth in business revenue scale for many consecutive years, serving a total of over 300 medium and large companies.</p> <p><br></p> <p>Please follow us on our Chinese and English websites cn.equalocean.com and equalocean.com to learn more about our business</p> <p><br></p>
November 30, 2022
<p>The precise regulation of RNA target sites is expected to regulate protein expression from upstream, intervene in traditionally undruggable targets, and control diseases.</p> <p>Rgenta Therapeutics, an innovative drug developer, announced its completion of a Series A round of financing worth USD 52 million. This funding round was led by AstraZeneca CICC Medical Industry Venture Fund (Chinese: 阿斯利康中金医疗产业基金), with participation from Korea Investment Partners, Delos Capital and the existing investors.</p> <p>The funds raised in this round will accelerate the construction of the R&D platforms for RNA-targeting small-molecule novel RNA drugs and the development of the pipelines.</p> <p>Founded in 2018, Rgenta is a biotechnology company that focuses on developing RNA-targeting medicines for historically undruggable targets to meet unmet clinical needs. The company closed a Seed round of financing worth USD 20 million in 2020. The investors were Boehringer Ingelheim Venture Fund, Matrix Partners China (Chinese: 经纬创投), Lilly Asia Ventures (Chinese: 礼来亚洲基金), Kaitai Capital (Chinese: 凯泰资本) and Legend Star Fund (Chinese: 联想之星).</p> <p>The development of small-molecule drugs usually targets proteins. However, only a quarter of the proteins implicated in human diseases are currently druggable by traditional approaches for developing small-molecule compounds. Exploring novel methods directly targeting RNA opens up unprecedented opportunities for drug development.</p> <p>Due to the structural characteristics of RNA and the complexity of related regulatory mechanisms, the development of small-molecule RNA-targeting medicines has a high threshold. Rgenta has built a proprietary platform that mines the massive genomics data to identify high-efficacy and high-specificity RNA target sites, and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Currently, the company is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.</p> <p>Relevant Chinese enterprises include Stemirna Therapeutics (Chinese: 斯微生物), Innorna (Chinese: 深信生物) and Ribo (Chinese: 瑞博生物).</p>
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
Founded in October 2018, EqualOcean International is an international information service provider and investment research firm that aims to become a global platform for industrial innovation.
EqualOcean took upon itself the mission of assisting promising Chinese companies in their quest to break into the global market. Join host Jason Poon for impactful news covering the technology, health, automotive, and consumer sectors.
This podcast updates daily.
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
No, this podcast does not typically feature guests.
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.